Look for any podcast host, guest or anyone

Showing episodes and shows of

SueWallSt

Shows

SueWallSt #109 $PYPL PayPal Branded Checkout Growth Story or Execution BreakdownIn this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $PYPL PayPal and its ambitious Branded Checkout growth targets. We examine Investor Day projections, twenty percent plus long term earnings goals, Venmo and buy now pay later expansion, slowing transaction payment volume growth, withdrawal of twenty twenty seven guidance, the CEO departure, and the twenty percent stock drop that followed. This deep dive is for fintech investors, growth stock traders, and anyone tracking earnings volatility, corporate governance, and securities litigation news. Visit ZLK.com for more info.

2026-03-0108 min

SueWallSt #108 $RGNX REGENXBIO Gene Therapy Breakthrough or Clinical Hold ShockIn this episode of Sue Wall Street Holding Wall Street Accountable, we examine the securities class action involving $RGNX REGENXBIO and its RGX 111 gene therapy for Hurler syndrome. We break down Phase One Phase Two safety statements, no drug related serious adverse events messaging, Fast Track designation, the later FDA clinical hold after a central nervous system tumor finding, and the seventeen percent stock drop that followed. This deep dive is for biotech investors, gene therapy traders, and anyone following FDA risk, clinical trial safety, and securities litigation news. Visit ZLK.com for more info. ...

2026-02-2809 min

SueWallSt #107 $QURE uniQure Gene Therapy Breakthrough or Regulatory ReversalIn this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $QURE uniQure and its AMT 130 gene therapy for Huntington disease. We examine the seventy five percent slowing claim, the Phase One Phase Two trial using an external control from ENROLL HD, the Biologics License Application timeline, the FDA reversal on study alignment, the three hundred forty five million dollar stock offering, and the forty nine percent stock drop. This deep dive is for biotech investors, healthcare traders, and anyone following gene therapy stocks, FDA approvals, clinical trial risk, and securities...

2026-02-2809 min

SueWallSt #106 $KD Kyndryl Controls in Place or Confidence CollapseIn this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $KD Kyndryl and alleged misstatements about internal controls over financial reporting. We examine IT general control weaknesses, cash flow misstatements, the late Form 10 Q filing, SEC Division of Enforcement inquiry, executive departures, and the fifty five percent stock drop that followed. This deep dive is for tech investors, corporate governance watchers, and anyone tracking accounting risk and securities litigation news. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not la...

2026-02-2708 min

SueWallSt #105 $INO Inovio Fast Track Dream or Regulatory RealityIn this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $INO Inovio Pharmaceuticals and its accelerated approval hopes for INO 3107 and the CELLECTRA device. We examine the Biologics License Application delay, manufacturing issues, FDA standard review decision, stock offerings, and the twenty four percent stock drop that followed. This deep dive is for biotech investors, healthcare traders, and anyone following FDA approvals, DNA medicines, regulatory risk, and securities litigation news. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not la...

2026-02-2709 min

SueWallSt #104 $PSFE Paysafe Payment Growth or Chargeback ShockIn this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $PSFE Paysafe and alleged undisclosed concentration risk in its ecommerce business. We examine revenue guidance, credit loss reserves, chargebacks tied to a high risk merchant, Merchant Category Code exposure, sponsor bank pressure, and the twenty seven percent stock drop that followed. This deep dive is for retail investors, fintech traders, and anyone tracking payment processing stocks, earnings volatility, and securities litigation news. Visit ZLK.com for more info. Add our WhatsApp Channel We’re...

2026-02-2707 min

SueWallSt #103 $TCPC BlackRock TCP Capital Steady NAV or Valuation ShockIn this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $TCPC BlackRock TCP Capital and alleged misstatements about net asset value, portfolio health, and non accrual investments. We examine NAV declines from ten dollars to near seven dollars, rising unrealized losses, restructuring efforts, and the sharp stock drops that followed. This deep dive is for income investors, BDC shareholders, and anyone tracking dividend stocks, credit risk, valuation practices, and securities litigation news. Visit ZLK.com for more info. Add our WhatsApp Channel We’re...

2026-02-2608 min

SueWallSt #102 $MREO Mereo BioPharma Stronger Bones or Shattered ExpectationsIn this episode of Sue Wall Street Holding Wall Street Accountable, we examine the securities class action involving $MREO Mereo BioPharma and its Phase Three ORBIT and COSMIC trials for setrusumab in osteogenesis imperfecta. We break down Phase Two bone mineral density data, missed fracture reduction endpoints, interim analysis results, the eighty seven percent stock collapse, and alleged misleading statements about clinical confidence. This deep dive is for biotech investors, healthcare traders, and anyone following rare disease drug development, clinical trial risk, and securities litigation news. Visit ZLK.com for more info. Add our WhatsApp...

2026-02-2607 min

SueWallSt #101 $RARE Ultragenyx Stronger Bones or Broken ThesisIn this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $RARE Ultragenyx and its Phase Three Orbit and Cosmic trials for setrusumab in osteogenesis imperfecta. We examine bone mineral density gains, failed fracture reduction endpoints, interim analysis results, the forty two percent stock drop, and alleged misleading statements about clinical trial confidence. This deep dive is for biotech investors, healthcare traders, and anyone following rare disease drug development, FDA pathways, and securities litigation news. Visit ZLK.com for more info. Add our WhatsApp Channel.

2026-02-2609 min

SueWallSt #100 $ORCL Oracle AI Spending Surge or Revenue Reality CheckIn this episode of Sue Wall Street Holding Wall Street Accountable, we examine the securities class action involving $ORCL Oracle and its massive artificial intelligence infrastructure expansion. We break down ballooning capital expenditures from twenty five billion to fifty billion dollars, negative free cash flow, two hundred forty eight billion dollars in lease commitments, insider stock sales, and the sharp stock drops that followed. This deep dive is for retail investors, tech stock traders, and anyone tracking AI investing, cloud computing, corporate governance, and securities litigation news. Visit ZLK.com for more info. Add our...

2026-02-2509 min

SueWallSt #099 $PLUG Plug Power Hydrogen Highway or Funding FreezeIn this episode of Sue Wall Street Holding Wall Street Accountable, we unpack the securities class action involving $PLUG Plug Power and its one billion six hundred sixty million dollar Department of Energy loan guarantee. We break down hydrogen production plans, the Texas facility, capital raises, executive departures, liquidity pivots, and the stock drops that followed. This deep dive is for retail investors, clean energy traders, and anyone following hydrogen stocks, DOE financing, and securities litigation news. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or ac...

2026-02-2508 min

SueWallSt #098 $PMI Picard Medical Artificial Heart or Artificial HypeIn this episode of Sue Wall Street Holding Wall Street Accountable, we examine the securities class action involving $PMI Picard Medical and its low float IPO, extreme stock volatility, and alleged social media stock promotion scheme. We break down the four dollar IPO, the rapid surge above thirteen dollars, the seventy percent collapse, WhatsApp trading groups, micro cap manipulation risks, and Rule 10b5 claims. This deep dive is for retail investors, IPO traders, and anyone following stock market news, pump and dump allegations, and securities litigation. Visit ZLK.com for more info. Add our WhatsApp...

2026-02-2507 min

SueWallSt #097 $RR Richtech Robotics AI Collaboration or Market ManipulationIn this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $RR Richtech Robotics and its headline making Microsoft AI collaboration. We analyze the press release language, the forty four percent stock surge, the thirty eight million dollar private placement, Microsoft’s denial of a commercial partnership, and the sharp stock drop that followed. This deep dive is for retail investors, tech stock traders, and anyone following AI investing, small cap stocks, and securities litigation news. Visit ZLK.com for more info. Add our WhatsApp Channel ...

2026-02-2408 min

SueWallSt #096 $METC Ramaco Resources Rock Solid Opportunity or Potemkin MineIn this episode of Sue Wall Street Holding Wall Street Accountable, we investigate the securities class action surrounding $METC Ramaco Resources and its rare earth minerals pivot at the Brook Mine. We break down the ribbon cutting event, alleged lack of mining activity, drone footage claims, SEC filings, stock drop, and Rule 10b5 allegations. This deep dive is for retail investors, traders, and anyone following stock market news, mining stocks, rare earth investing, and securities litigation. Visit ZLK.com for more info. Add our WhatsApp Channel We’re not lawyers or accountants, so...

2026-02-2407 min

SueWallSt #095 $BYND Beyond Meat Sizzles or Burns InvestorsIn this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action surrounding $BYND Beyond Meat and its alleged asset impairment and disclosure issues. We explore EBITDA goals, non cash impairment charges, SEC filings, stock drops, and what it all means for shareholders. This deep dive is for retail investors, traders, and anyone interested in stock market news, securities litigation, and corporate transparency. Visit ZLK.com for more info. Add our WhatsApp Channel We’re not lawyers or accountants, so don’t take this as legal or fina...

2026-02-2407 min

SueWallSt #094 $BRBR Shakes and Red Flags What BellRing Didn’t Tell InvestorsIn this episode of Sue Wall Street Holding Wall Street Accountable we break down the explosive class action lawsuit against BellRing Brands Inc $BRBR the company behind Premier Protein. This podcast is for investors shareholders and anyone curious about stock market lawsuits securities fraud and corporate accountability. We dive deep into alleged misrepresentations inventory stockpiling hidden demand issues and competitive pressures with clear explanations real world context and a bit of sharp commentary. Expect an investigative deep dive with analysis and plain English breakdowns designed to help retail investors stay informed and alert. Visit ZLK...

2026-02-0506 min

SueWallSt #093 Smoked by Smart Digital: The $SDM Social Media Pump-and-Dump$SDM Smart Digital Group rocketed from $4 to nearly $30 per share then crashed over 85% amid allegations of a massive market manipulation scheme. In this episode of Sue Wall Street: Holding Wall Street Accountable, we expose how fake advisors, WhatsApp hype, and crypto buzz drove a meteoric rise… and a brutal collapse. If you're into IPO scams, SEC drama, and investor deception this one’s for you. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2026-01-2808 min

SueWallSt #092 Mist Opportunity: The $VTGN Drug Trial That Vaporized Millions$VTGN Vistagen Therapeutics hyped its anxiety drug fasedienol as a game-changer but when the Phase 3 trial failed, the stock plummeted 80% in one day. In this episode of Sue Wall Street: Holding Wall Street Accountable, we break down the lawsuit accusing $VTGN of misleading investors with overly optimistic projections while hiding known risks tied to flawed trial design. If you're into biotech drama, trial data spin, and sudden stock collapses don’t miss it. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take t...

2026-01-2806 min

SueWallSt #091 Concrete Delays and Cloudy Claims: The $CRWV Collapse$CRWV CoreWeave rocketed 349% after its IPO, fueled by AI hype and a $11.9B OpenAI deal. But when delayed data centers, rainy Texas weather, and missed guidance hit, the stock cratered and now they’re facing a class action lawsuit. In this episode of Sue Wall Street: Holding Wall Street Accountable, we unpack the allegations of securities fraud, infrastructure failure, and inflated projections that have investors crying foul. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice

2026-01-2707 min

SueWallSt #090 Scent of a Sell-Off: The $BBWI Strategy That Backfired$BBWI Bath & Body Works touted its bold pivot "adjacencies, collaborations, and promotions" as the key to growth. But a class action lawsuit now claims that strategy masked core business struggles, ultimately leading to a 25% stock drop. In this episode of Sue Wall Street: Holding Wall Street Accountable, we dive into what investors were told, what was allegedly left out, and why this fragrance-forward brand is now fighting legal fires. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or f...

2026-01-2708 min

SueWallSt #089 Flatlining Finances: The $ARDT IPO That Misdiagnosed Itself$ARDT Ardent Health pitched precision and transparency in its IPO but behind the scenes, it was relying on a flawed accounting method that allegedly overstated revenue by $43M and masked malpractice risks with underfunded reserves. In this episode of Sue Wall Street: Holding Wall Street Accountable, we examine the class action accusing $ARDT of inflating its value with outdated assumptions and misleading disclosures. If you care about healthcare, Wall Street truth, and IPO red flags don’t miss this one. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not...

2026-01-2607 min

SueWallSt #088 Security Breach, Security Pitch: The $FFIV Fallout$FFIV F5, Inc. told investors they offered “best-in-class” cybersecurity while hackers allegedly had long-term access to their top revenue-generating product. In this episode of Sue Wall Street: Holding Wall Street Accountable, we unpack the class action lawsuit claiming $FFIV concealed a serious security breach for over two months, misleading shareholders and triggering a double-digit stock drop. If you follow cybersecurity, corporate accountability, or tech-sector lawsuits this one’s for you. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or f...

2026-01-2608 min

SueWallSt #087 Glitch in the Cloud: The $VRNS SaaS Collapse$VRNS Varonis Systems told investors their cloud transition was smooth sailing until the stock crashed nearly 49% overnight. In this episode of Sue Wall Street: Holding Wall Street Accountable, we dig into the class action lawsuit alleging executives misled shareholders while renewal rates crumbled and SaaS conversions stalled. If you're into cybersecurity, tech drama, or Wall Street accountability, you won’t want to miss this. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2026-01-2507 min

SueWallSt #086 Coup-oops: The $CPNG Data Breach That Shook a Nation$CPNG Coupang faces a class action lawsuit after failing to promptly disclose a massive data breach affecting over 33 million users two-thirds of South Korea’s population. In this episode of Sue Wall Street: Holding Wall Street Accountable, we break down how a former employee’s unchecked access led to regulatory raids, executive fallout, and a stock drop that left investors reeling. If you're into cybersecurity failures, disclosure law, and corporate accountability this one’s a must-listen. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t...

2026-01-2407 min

SueWallSt #085 Student Debt Surprise: The $SLM Lawsuit You Didn't See ComingWhen $SLM Sallie Mae told investors delinquencies were just seasonal, no one expected an 8% stock drop days later. In this episode of Sue Wall Street: Holding Wall Street Accountable, we break down the class action lawsuit alleging $SLM misled shareholders while student loan defaults quietly spiked. If you’re an investor, borrower, or just love financial plot twists, this one’s for you. Expect sharp analysis, real talk, and a deep dive into what went wrong. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don...

2026-01-2307 min

SueWallSt #084 Buy Now Sue Later: The $KLAR IPO BlowupWhat do burritos, high-interest loans, and a fintech IPO have in common? In this episode of Sue Wall Street: Holding Wall Street Accountable, we dive into the lawsuit against $KLAR Klarna, accused of misleading investors about its “responsible” lending model while financing fast food purchases at nearly 36% APR. If you're into fintech drama, IPO fails, or consumer finance red flags, this one’s for you. We break it down with sharp insights and just the right amount of spice. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers...

2026-01-2307 min

SueWallSt #083 Meltdown Mode: The $FRMI Fallout After the HypeWhat happens when an AI-powered nuclear dream crashes into SEC reality? In this episode of Sue Wall Street: Holding Wall Street Accountable, we unpack the class action lawsuit against $FRMI Fermi Inc.—the company that raised nearly $750M in its IPO but is now accused of misleading investors over its Project Matador energy campus. If you're into IPO drama, financial deep dives, or the intersection of AI and energy, this episode is for you. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take...

2026-01-2207 min

SueWallSt #082 Cloudy with a Chance of Litigation: The $AGL ShakeupWhen $AGL Agilon Health promised strong 2025 numbers, investors listened. But a sudden CEO exit, scrapped financial guidance, and a massive earnings miss sent shares plunging over 50%. In this episode of Sue Wall Street: Holding Wall Street Accountable, we dive deep into the class action lawsuit accusing $AGL of misleading shareholders. If you're an investor, finance buff, or legal drama fan this one's for you. We break it down with sharp analysis and a touch of humor. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so...

2026-01-2206 min

SueWallSt #081 $ITGR Flatlines: Firefighters Fund Sues Over Shock DropWhen heart devices disappoint, portfolios can too. In this episode of Sue Wall Street, we dive into the class action lawsuit against Integer Holdings $ITGR, filed by the West Palm Beach Firefighters’ Pension Fund. Accusations fly over allegedly misleading statements about cardiac tech demand, leading to a brutal 32% stock crash. If you’re an investor, whistleblower, or just tracking medtech markets, this one’s for you. Expect sharp analysis, real talk, and no sugarcoating. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take thi...

2025-12-2307 min

SueWallSt #080 Feathers Fly at $OWL: Investors Cry Foul Over Redemption FreezeBlue Owl Capital $OWL is in the hot seat after a surprise merger move left some investors trapped and staring down a 20 percent loss. In this episode of Sue Wall Street, Cassie and Bill unravel what went down with the halted redemptions, the OBDC merger, and the class action lawsuit that followed. This one’s for investors, financial watchdogs, and anyone tracking the private credit boom. Expect deep dives, sharp banter, and no fluff just facts. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so d...

2025-12-2207 min

SueWallSt #079 $STUB’s Post-IPO Faceplant StubHub Sued Over Cash Flow CollapseStubHub $STUB went public with fanfare then revealed a 143% plunge in free cash flow just weeks later. In this episode of Sue Wall Street, Cassie and Bill break down the class action lawsuit alleging StubHub’s IPO disclosures misled investors by hiding critical financial trends. With big-name underwriters and a 56% stock drop, this one's a must-listen for IPO watchers and retail investors. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-12-1806 min

SueWallSt #078 $SFM’s Organic Illusion Sprouts' Stock Tanks After “Tailwind” Talk WiltsSprouts Farmers Market $SFM hyped consumer “tailwinds” and raised guidance in July then slashed forecasts three months later, triggering a 26% stock plunge in one day. In this episode of Sue Wall Street, Cassie and Bill dig into the class action lawsuit alleging misleading optimism, ignored internal data, and inflated growth projections. Perfect for retail investors, ESG followers, and anyone tracking grocery sector drama. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-12-1707 min

SueWallSt #077 $JYD’s 95 Percent Crash How Jayud’s Pump and Dump UnraveledJayud Global Logistics $JYD soared from $1 to nearly $8—then collapsed 95% overnight. In this episode of Sue Wall Street, we dive into the class action lawsuit alleging a coordinated pump-and-dump scheme, misleading financials, and silence from auditors. With fake stock tips, insider control, and offshore structures, investors say this was built to blow. Perfect for retail traders, audit watchdogs, and market skeptics. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-12-1608 min

SueWallSt #076 $DEFT's Crypto Mirage DeFi Technologies’ “Low-Risk” Strategy ImplodesDeFi Technologies $DEFT promised a low-risk, high-reward crypto arbitrage strategy through its DeFi Alpha desk claiming steady returns and booming growth. But after raising $100M from investors, they quietly admitted those trades weren’t happening. In this episode of Sue Wall Street, Cassie and Bill break down the lawsuit alleging securities fraud, inflated projections, and a CEO exit. For crypto investors, fintech skeptics, and anyone watching the digital asset space. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal...

2025-12-1507 min

SueWallSt #075 $BTDR’s Crypto Chip Collapse Bitdeer’s SEALMINER Hype Turns into a LawsuitBitdeer Technologies $BTDR hyped its revolutionary SEALMINER A4 chip as a game-changer in Bitcoin mining claiming cutting-edge efficiency and breakthrough innovation. But when the real numbers dropped, the chip underperformed, delays piled up, and the stock plunged over 14% in a day. In this episode of Sue Wall Street, we unpack the lawsuit accusing Bitdeer of misleading investors and inflating expectations. For crypto traders, tech investors, and market skeptics. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or fina...

2025-12-1406 min

SueWallSt #074 $ARE's Megacampus Meltdown The Truth Behind Alexandria's $323M BombshellAlexandria Real Estate $ARE touted its Long Island City property as a cornerstone of life sciences growth—until a shocking $323.9M impairment revealed the cracks. In this episode of Sue Wall Street, Cassie and Bill unpack the securities fraud allegations, the alleged “megacampus” misrepresentations, and why investors say they were misled. Perfect for real estate investors, REIT-watchers, and anyone tracking Wall Street transparency. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-12-1307 min

SueWallSt #073 $SKYE's Weight Loss Wipeout When Biotech Hype Meets RealitySkye Bioscience $SKYE promised a breakthrough obesity drug—but when human trial results dropped, it didn’t even outperform a placebo. The stock plunged 60% in one day, and now executives are accused of cashing out while pumping up investor expectations. This episode of Sue Wall Street breaks down the lawsuit, the science spin, and what it means for biotech investors, traders, and anyone chasing the next pharma moonshot. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financia...

2025-12-1207 min

SueWallSt #072 $PRGO's Formula for Disaster How Perrigo’s Baby Bet BackfiredPerrigo $PRGO plunged 25 percent in one day after announcing a full review of its infant formula business—just two years after acquiring it. In this episode of Sue Wall Street, Cassie and Bill unpack how $240M in planned investments, rosy projections, and mounting losses turned into allegations of securities fraud. If you’re an investor, legal buff, or love corporate drama, this one's for you. Expect sharp takes, deep dives, and straight talk on shareholder rights. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don...

2025-12-1108 min

SueWallSt #071 $TLX in Hot Water Telix Faces SEC Heat Over Drug Development DisclosuresTelix Pharmaceuticals $TLX is facing a federal subpoena and a scorching class action lawsuit after allegedly misleading investors about its prostate cancer drug pipeline and FDA compliance. In this episode of Sue Wall Street, we dive into how missing trial data, shady supply chain claims, and a bombshell FDA rejection sent the stock tumbling. Ideal for biotech investors, legal watchers, and anyone tracking pharmaceutical accountability. Get the facts, not just the filings. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this...

2025-11-3007 min

SueWallSt #070 $PRMB’s Merger Meltdown From “Flawless” to a $2 Billion BlowupPrimo Brands $PRMB told investors their mega-merger was going “flawlessly” but behind the scenes, tech failures, service chaos, and internal breakdowns were flooding the company. In this episode of Sue Wall Street, we unpack how confident corporate spin turned into a shareholder disaster and triggered a class action lawsuit after a stunning 36% stock drop. If you follow M&A hype, beverage brands, or securities fraud cases, this one’s for you. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal o...

2025-11-2907 min

SueWallSt #069 $LRN’s Ghost Students The EdTech Scandal That Rocked Wall StreetOnline learning giant Stride Inc $LRN is under fire for allegedly inflating enrollment with “ghost students” to boost funding triggering a massive stock crash and a class action lawsuit. In this episode of Sue Wall Street, we dive into whistleblower claims, fake student rosters, overworked teachers, and missed special ed services. Perfect for investors, educators, and anyone tracking EdTech accountability. Expect shocking details, legal breakdowns, and stock fallout. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financia...

2025-11-2807 min

SueWallSt #068 $FLY and Fall Firefly’s IPO Burns Investors in Rocket LawsuitFirefly Aerospace $FLY promised liftoff but shareholders got a crash landing. In this episode of Sue Wall Street, we break down how failed rocket launches, FAA groundings, and misleading IPO statements led to a fiery class action lawsuit. If you're into space stocks, IPO hype, or financial accountability, this is your orbit. Expect sharp analysis, timeline breakdowns, and insider commentary. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-11-2707 min

SueWallSt #067 $FCX Under Fire The Mudslide That Sparked a Shareholder ShowdownA deadly mud rush at Freeport-McMoRan’s $FCX Grasberg mine in Indonesia has triggered more than tragedy it’s now the center of a major class action lawsuit. In this gripping episode of Sue Wall Street, we break down how safety failures, misleading disclosures, and a steep stock plunge are fueling investor outrage. If you're into mining stocks, ESG accountability, or securities law drama, this one’s for you. Expect expert analysis, real talk, and financial firepower. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accounta...

2025-11-2607 min

SueWallSt #066 Molina’s $MOH Meltdown Two Guidance Cuts One LawsuitMolina Healthcare $MOH stunned investors by slashing earnings forecasts—twice—in just two weeks, triggering a stock freefall and a major class action lawsuit. This episode of Sue Wall Street dives into how inflated guidance, hidden medical cost spikes, and shocking disclosures led to shareholder chaos. Perfect for investors, finance nerds, and corporate accountability watchdogs. Expect sharp commentary, deep dives, and eye-popping numbers. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-11-2607 min

SueWallSt #065 $AVTR Meltdown Avantor’s Lab-Grade Confidence Evaporates in CourtIn this episode, we break down the class action lawsuit against Avantor $AVTR after the life sciences giant allegedly misled investors while bleeding accounts, slashing guidance, and posting a massive $785M goodwill impairment. From rosy earnings calls to brutal stock drops, we reveal how investor trust evaporated. Perfect for biotech watchers, institutional investors, and Wall Street skeptics. Get legal insights, sharp commentary, and real accountability. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-11-2307 min

SueWallSt #064 $DXCM Drops the Ball DexCom’s Sensor Scandal Shocks InvestorsThis episode exposes the class action lawsuit against DexCom $DXCM after unauthorized changes to its G6 and G7 glucose sensors sparked FDA warnings, tragic outcomes, and a brutal stock plunge. We break down how misleading safety claims and insider stock sales may have violated securities laws. Ideal for medtech investors, financial sleuths, and patient advocates. Expect sharp takes, real cases, and deep accountability. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-11-2207 min

SueWallSt #063 $INSP Implodes The Sleep Apnea Launch That Put Investors to BedWe uncover the class action lawsuit against Inspire Medical Systems $INSP after their highly touted Inspire V rollout turned out to be a total sleepwalking disaster. From training failures to billing chaos and low demand, the company painted a glowing picture while reality burned. Perfect for investors, analysts, and anyone tracking medtech risks. Expect sharp breakdowns, legal insight, and cautionary tales. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-11-2107 min

SueWallSt #062 $KMX Misfires How CarMax’s “Tariff Turbo” Turned into a Legal TailspinIn this episode, we dig into the class action lawsuit against CarMax $KMX after a 20 percent stock nosedive. Did execs hype their financials during a short-lived buying boom fueled by tariff rumors? Investors say yes and the legal fallout could shake up how companies spin short-term wins. Ideal for retail traders, shareholders, and finance buffs. Expect sharp banter, legal insights, and Wall Street accountability. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-11-2007 min

SueWallSt #061 Chipwreck at $SNPS When Custom AI Deals Collide with Wall StreetThis episode dives into the class action lawsuit rocking Synopsys $SNPS after a shocking 35 percent stock crash. We unpack how high-maintenance AI clients strained their chip IP business, leading to missed earnings, dropped guidance, and serious allegations of misleading investors. Perfect for retail investors, traders, and finance-curious tech watchers. Expect sharp banter, lawsuit breakdowns, and market lessons in every episode. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-11-2006 min

SueWallSt #060 Chemical Reaction The $AVTR Lab Meltdown LawsuitAvantor $AVTR claimed strength in biotech and life sciences but behind the beakers, they allegedly masked shrinking margins, lost key clients, and overstated growth. In this episode of Sue Wall Street, we break down the class action accusing Avantor of misleading investors, inflating valuations, and triggering a 25% stock slide. If you're into biotech markets, investor rights, or corporate accountability, don’t miss this one. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-11-1307 min

SueWallSt #059 Contract Terminated The $KBR Military Move Meltdown$KBR claimed 90% satisfaction on its military relocation contract—just weeks before the Department of Defense abruptly canceled it. In this episode of Sue Wall Street, we unpack the lawsuit alleging KBR misled investors, downplayed operational issues, and triggered a sudden 10% stock drop. If you follow defense contractors, government deals, or securities litigation, this one's for you. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-11-1207 min

SueWallSt #058 Bottle Service and Balance Sheets The $RICK Tax Fraud Blowup$RICK is under fire after a bombshell lawsuit alleged a decade-long tax fraud scheme, complete with bribes, falsified books, and “Dance Dollars.” In this episode of Sue Wall Street, we unpack how RCI Hospitality Holdings' adult entertainment empire spiraled into a 79-count criminal indictment and a 25% stock crash. Perfect for investors, compliance pros, and anyone tracking corporate scandal in the wildest corners of Wall Street. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-11-1207 min

SueWallSt #057 Spreadsheet Sorcery The $MRX Accounting Smoke ShowMarex Group $MRX faces a rare class action brought by short sellers who claim they were misled by inflated revenues, off-book intercompany trades, and hundreds of millions in misstated cash flows. In this episode of Sue Wall Street, we dissect the alleged financial illusion: from fake operating cash flow to hidden hedge fund risks and serial restatements. If you're into forensic accounting, short-selling chaos, or global finance drama this one’s for you. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this a...

2025-11-1107 min

SueWallSt #056 Firewall Smoke and Mirrors The $FTNT Refresh Cycle FalloutFortinet $FTNT hyped a historic firewall refresh, claiming it would drive $450M in revenue. But behind the scenes, nearly half the cycle had already happened—quietly and with minimal impact. In this episode of Sue Wall Street, we break down the class action lawsuit alleging Fortinet misled investors, overstated growth, and triggered a 22% stock crash. Perfect for investors, finance pros, and anyone tracking tech accountability. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-11-1107 min

SueWallSt #055 Cracks in the Foundation The $JHX Stock Slide ExplainedJames Hardie Industries $JHX claimed strong demand and normal inventory levels—but investors were blindsided when sales tanked and the stock dropped over 34 percent in just two days. In this episode of Sue Wall Street, we unpack the class action lawsuit alleging misleading statements, channel stuffing, and executive-level coverups. Perfect for retail investors, legal watchers, and finance sleuths. Get deep-dive analysis, sharp commentary, and red-flag warnings. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-11-1105 min

SueWallSt #054 $BAX and the IV Pump That Sparked a Securities Storm$BAX Baxter International is under fire after its “next-gen” infusion pump allegedly caused injuries, deaths and then a 22% stock plunge. In this episode of Sue Wall Street, we unpack the class action lawsuit claiming Baxter concealed life-threatening defects in its Novum IQ pump while touting its success to investors. If you're into medical tech, shareholder rights, or corporate cover-ups, tune in. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-10-3108 min

SueWallSt #053 $MLTX MoonLake’s Nanobody Nightmare$MLTX MoonLake Immunotherapeutics lost nearly 90% of its stock value in one day after clinical trial results for its flagship nanobody drug disappointed investors. In this episode of Sue Wall Street, we dissect the class action lawsuit accusing MoonLake of hyping unproven biotech claims and misleading the market. If you follow biotech stocks, clinical trial risk, or Wall Street spin, don’t miss this one. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-10-3107 min

SueWallSt #052 $ATYR’s Biotech Hype Falls Flat in One Day$ATYR aTyr Pharma promised a steroid-free future with its experimental drug—but when their Phase 3 trial failed to meet its endpoint, the stock collapsed 83% in a single day. In this episode of Sue Wall Street, we unpack the class action lawsuit alleging investors were misled by overly optimistic claims. Biotech investors, clinical trial watchers, and Wall Street skeptics—this one's a must-listen. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-10-3108 min

SueWallSt #051 $WPP’s Ad Forecast Flops into a Lawsuit$WPP told investors 2025 would be steady even “cautiously optimistic.” Then came the surprise: plummeting revenues, CEO retirement, and a trading update that sparked an 18% stock drop. In this episode of Sue Wall Street, we break down the securities class action accusing the global ad giant of misleading investors with overconfident projections. If you're into ad tech, investor risk, or corporate spin, this one's for you. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-10-3107 min

SueWallSt #050 $SVRA’s Inhaled Hype Hits a WallWhen $SVRA Savara Inc. filed its long-awaited FDA application, investors cheered—until the FDA refused to even review it. In this episode, we dive into the unfolding securities class action accusing Savara of misleading shareholders about its incomplete drug submission. Biotech investors, pharma followers, and Wall Street skeptics this one's for you. Expect sharp breakdowns, timely analysis, and a dose of biotech drama. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-10-3107 min

SueWallSt #049 Trouble in the Tint: What’s Going on with $TROX?A fresh class action lawsuit is shaking up $TROX Tronox Holdings, after investors claim the company misled them with glowing projections and shaky forecasting. In this episode of Sue Wall Street, we dive into how a drop in demand, a slashed dividend, and a brutal 38% stock plunge triggered legal action. If you're an investor, trader, or just love corporate drama, tune in for sharp insights, expert analysis, and sarcastic pigment puns. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or f...

2025-10-3106 min

SueWallSt #048 $VFC’s Reinvent or Misrepresent The Vans Reset That Shocked ShareholdersWas $VFC walking investors into a turnaround—or a trap? In this episode of Sue Wall Street, we dive into the class action lawsuit against V.F. Corporation, the company behind Vans, The North Face, and Timberland. While hyping its “Reinvent” strategy, VFC allegedly hid plans for a second major reset—until surprise earnings revealed a 20% Vans revenue drop. If you follow retail stocks, brand comebacks, or securities litigation, this one's for you. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as...

2025-10-0207 min

SueWallSt #047 $CYTK’s Approval Delay The Biotech Oversight That Rocked InvestorsDid $CYTK gamble with the FDA and lose investor trust? In this episode of Sue Wall Street, we unpack the class action lawsuit against Cytokinetics Inc. Despite strong Phase 3 results, the company skipped a critical REMS in their NDA, delaying drug approval and tanking their stock. If you're into biotech moves, FDA filings, or securities law drama, this deep dive is for you. Learn how one missing document may cost shareholders millions. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as l...

2025-10-0107 min

SueWallSt #046 $FLR’s Bridge to Nowhere How Fluor’s Earnings Collapse Sparked a Class ActionWas $FLR engineering confidence or just misleading investors? In this episode of Sue Wall Street, we dive into the securities class action lawsuit against Fluor Corporation. If you're tracking construction giants, infrastructure deals, or suspiciously sunny earnings calls, this one’s for you. We unpack how project delays, cost overruns, and executive stock sales all led to a brutal 27% drop in one day—and a whole lot of legal fallout. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or...

2025-09-2907 min

SueWallSt #045 The $SVRA Smokescreen How a Missing Drug File Crushed ShareholdersWhat happens when a biotech company tells investors one thing and delivers another? In this episode of Sue Wall Street, we unpack the securities class action against Savara Inc. $SVRA’s inhaled drug for rare lung disease was supposed to be a breakthrough—until the FDA refused to even review their application. If you're a biotech investor, compliance nerd, or just love a good Wall Street unraveling, this deep dive is for you. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take thi...

2025-09-2907 min

SueWallSt #044 Pylarify Panic The $LNTH Lawsuit Wall Street Didn’t See ComingWas $LNTH hiding the truth? In this episode of Sue Wall Street, Cassie and Bill unpack the shocking securities class action lawsuit against Lantheus Holdings. Biotech investors, this one’s for you: we dig into Pylarify’s pricing fallout, executive silence, and a stock freefall that left shareholders stunned. Expect sharp analysis, legal breakdowns, and just enough outrage to fuel your next portfolio check. Whether you’re into earnings calls, SEC filings, or drama on the NASDAQ, tune in. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers...

2025-09-2807 min

SueWallSt #043 $TSLA Swerves Into Legal Trouble Are Robotaxis the New Risk?Tesla’s $TSLA Robotaxi dreams hit a legal speed bump. In this episode of Sue Wall Street, we dive deep into the securities class action targeting Tesla and Elon Musk. Shareholders allege misleading claims about autonomous driving tech, safety, and AI, all while the stock took a sharp turn. Perfect for investors, financial sleuths, and courtroom junkies. Expect insider details, analysis, and sharp banter. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-09-2705 min

SueWallSt #042 $NVO’s 25 Percent ProblemNovo Nordisk $NVO promised blockbuster weight loss from its new drug CagriSema—touting 25% results. But when final trial data landed at 22.7%, investors were stunned. In this episode of Bulls & Betrayal, Anna and Nate dig into the class action lawsuit accusing Novo of misleading shareholders about trial design and results. Perfect for biotech investors, legal watchers, and pharma skeptics, this episode exposes the risks behind drug hype. Add our WhatsApp Channel. Visit ZLK.com for more info. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-09-2608 min

SueWallSt #041 $LMT Crashes Under Classified PressureLockheed Martin $LMT is facing a massive class action after revealing nearly $5 billion in losses tied to secretive government contracts. In this episode of Sue Wall Street, Cassie and Bill unravel how one of the largest defense contractors allegedly misled investors while quietly hemorrhaging money. Perfect for retail investors, financial sleuths, and anyone watching corporate accountability, this deep dive blends drama, SEC filings, and shareholder lawsuits. Add our WhatsApp Channel. Visit ZLK.com for more info. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-09-2507 min

SueWallSt #040 $SOC Slips on Spilled HypeWhen Sable Offshore $SOC announced its oil production had resumed, investors rushed in—and the stock jumped 14%. But the truth? No real restart, just well testing. In this episode of Sue Wall Street, Cassie and Bill uncover how one press release, one $295M secondary offering, and one harsh reality check triggered a class action lawsuit. Perfect for investors, analysts, and compliance pros, this episode blends sharp commentary with deep legal insight. Add our WhatsApp Channel. Visit ZLK.com for more info. We’re not lawyers or accountants, so don’t take this as...

2025-09-2506 min

SueWallSt #039 $LINE Goes Cold Inside the IPO That Left Investors Out in the Cold$LINE’s blockbuster IPO raised billions—but did it freeze out the truth? In this episode of Sue Wall Street, we unpack the class action lawsuit alleging Lineage misled investors about plunging demand, evaporating inventory, and a deep freeze in fundamentals. With private equity payouts, post-COVID market distortions, and a fired auditor, this case is a must-listen for IPO investors, pension funds, and anyone tracking Wall Street accountability. Expect deep dives, sharp takes, and frosty truths. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t...

2025-09-2307 min

SueWallSt #038 $FLYW Grounded How Student Visas Crashed Flywire’s Growth StoryWhen $FLYW’s stock plunged 37% in a single day, investors were blindsided. In this episode of Sue Wall Street, we break down the new class action lawsuit accusing Flywire of downplaying massive headwinds from international student visa caps while hyping their growth narrative. If you're into SaaS stocks, fintech drama, or shareholder rights, this one's for you. Expect insider breakdowns, sharp commentary, and red flags you don’t want to miss. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or...

2025-09-2206 min

SueWallSt #037 $FI’s Clover Crisis The Truth Behind Fiserv’s Growth ClaimsWas $FI’s explosive growth just a billing trick? In this episode of Sue Wall Street, we unpack the class action lawsuit alleging that Fiserv misled investors by calling forced migrations to its Clover platform "organic growth." Small businesses pushed off the Payeezy system didn’t stick around—and when they fled, the stock followed. If you're a fintech investor, shareholder advocate, or SEC rules junkie, this one's for you. Expect exposés, sharp analysis, and unraveling KPIs. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountan...

2025-09-2108 min

SueWallSt #036 $DOW Drops the Ball The Dividend Cut Heard Around Wall StreetWhen $DOW slashed its dividend by 50% after months of rosy forecasts, investors were left reeling—and a securities fraud lawsuit quickly followed. In this episode of Sue Wall Street, we unpack the allegations that Dow Inc. misled shareholders about financial stability, masking demand drops and oversupply issues in key markets. Perfect for retail investors, dividend chasers, and finance nerds who love a good Wall Street reckoning. Expect sharp commentary, deep dives, and corporate accountability. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take t...

2025-09-2007 min

SueWallSt #035 ALT-erred Expectations What Went Wrong at $ALTBiotech dreams turned into investor nightmares when $ALT stock plummeted 53% overnight after failing a key endpoint in its MASH drug trial. In this episode of Sue Wall Street, we break down the class action lawsuit accusing Altimmune of hyping results and misleading shareholders. Perfect for investors, biotech watchers, and legal buffs, this episode mixes deep-dive analysis with sharp commentary. Expect insider breakdowns, trial missteps, and the legal firestorm that followed. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or f...

2025-09-1907 min

SueWallSt #034 $XYZ Insider Trading Could Cost You Millions and 20 YearsIn this episode of Sue Wall Street, we expose the serious legal consequences of $XYZ insider trading—from multi-million dollar fines to decades behind bars. Whether you’re trading on a hot tip or just “sharing” info, the SEC and DOJ don’t play around. We break down tipping, penalties, and why ignorance won’t save you. Perfect for retail traders, finance professionals, and anyone at risk of overhearing the wrong thing at a backyard BBQ. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take thi...

2025-09-1906 min

SueWallSt #033 $XYZ Whistleblowers Wanted: How to Report Insider Trading Like a ProIn this episode of Sue Wall Street, we dig into the high-stakes world of insider trading—what it is, how to spot it, and how you can report it through the SEC Whistleblower Program. From shady trades to million-dollar rewards, we cover the process, anonymity options, and real risks of retaliation. If you're an investor, employee, or just someone with a suspicious eye, this guide is for you. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice

2025-09-1809 min

SueWallSt #032 The $FLYE Fall: When EV Hype Goes Up in Smoke$FLYE Fly-E Group soared on promises of urban mobility and government-backed safety programs—then crashed 87% in a day after battery explosions and revenue drops came to light. In this episode of Sue Wall Street, we expose the class action lawsuit alleging Fly-E misled investors about lithium battery risks and future growth. Perfect for EV investors, startup skeptics, and anyone watching the electric mobility space crash into regulatory reality. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-09-1807 min

SueWallSt #031 $XYZ Under Fire When Fiduciary Duties Get DumpedIn this episode of Sue Wall Street, we unpack what happens when company execs treat fiduciary duties like a suggestion not a requirement. From insider enrichment to reckless decisions masked as “business judgment,” we break down how shareholders get burned and how class actions try to restore accountability. If you’ve ever owned stock or trusted a CEO, this one’s for you. Great for retail investors, governance nerds, and legal-watchers. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or fin...

2025-09-1707 min

SueWallSt #030 From $ANRO to Uh-Oh: When Biotech Dreams FlatlineIn this episode of Sue Wall Street, Cassie and Bill dive into the spectacular collapse of $ANRO Alto Neuroscience. After raising $119M in its 2024 IPO on hopes of revolutionizing psychiatry, its flagship drug ALTO-100 flunked a critical trial—sending shares plummeting nearly 70%. We unpack the lawsuit alleging misleading IPO documents, dig into the risks of precision medicine, and ask: was this hype or just heartbreak? Perfect for investors, biotech watchers, and anyone tracking Wall Street accountability. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’...

2025-09-1607 min

SueWallSt #029 $XYZ and the Fine Print Trap: When Financial Projections MisleadIn this episode of Sue Wall Street we breakdown of how companies like $XYZ use slick summaries, cherry-picked data, and non-GAAP tricks to inflate projections and potentially deceive investors. We explore what counts as misleading, when safe harbor doesn't apply, and how class actions kick off after the truth hits. If you're an investor, analyst, or just tired of corporate spin, this one's for you. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-09-1609 min

SueWallSt #028 $TROX Tumbles After Forecasts Flop and Lawsuit FollowsWhat happens when a pigment powerhouse promises shine but delivers a splatter? In this episode of Sue Wall Street, we break down the class action lawsuit against $TROX Tronox Holdings after the company hyped up bullish forecasts—then slashed guidance and dividends when the truth hit. Perfect for investors, analysts, and market watchers who want the inside scoop on flawed forecasts, chemical industry volatility, and how one earnings report triggered a 38% drop. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or fin...

2025-09-1606 min

SueWallSt #027 $SMLR Slips as DOJ Investigation and $29M Settlement Come to LightOn this episode of Sue Wall Street, we dig into the DOJ’s five-year shadow investigation into $SMLR and why Semler Scientific never told investors. While hyping up compliance risks, the company failed to disclose five civil investigative demands and a looming $29.75M settlement tied to its QuantaFlo device. With shares dropping and trust eroding, this class action could reshape medical device disclosures. For retail investors, healthcare analysts, and compliance hawks. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal...

2025-09-1507 min

SueWallSt #026 $NUTX Faces Legal Shock After Surprise Profits Raise Fraud FlagsThis week on Sue Wall Street, we unpack the wild ride behind $NUTX—from skyrocketing arbitration profits to a scathing short-seller report alleging fraud. Nutex Health's partnership with HaloMD, now under fire, may have fueled inflated revenues and shareholder deception. With missed filings, internal control failures, and a looming restatement, this class action could shake up the healthcare sector. Ideal for retail investors, healthcare analysts, and fraud sleuths. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice

2025-09-1507 min

SueWallSt #025 Meltdown at $REPL: When Cancer Trials Go ColdWhen a biotech darling gets FDA-snubbed, investors feel the burn. In this episode of Sue Wall Street, we dig into the class action lawsuit against $REPL Replimune after its cancer trial bombed and the FDA called it “not adequate or well-controlled.” If you're a biotech investor, trader, or market skeptic, this one’s for you. Expect sharp commentary, legal breakdowns, and eye-popping stock drops as we unpack what went wrong — and what comes next. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or...

2025-09-1407 min

SueWallSt #024 Blurry Vision at $RXSTWhat happens when a med-tech marvel hits a legal wall? In this episode of Sue Wall Street, we unpack the class action lawsuit against $RXST RxSight Inc — the company behind light-adjustable lenses and even brighter promises. Ideal for investors, market watchers, and anyone tracking the Nasdaq's medical tech space. Expect deep dives, sharp analysis, and sharp-tongued banter as we expose how strong earnings masked hidden “adoption challenges.” Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.

2025-09-1307 min

SueWallSt #023 $PUBM Plunges as Lawsuit Unpacks Hidden Ad Tech Shake-UpIn this episode of Sue Wall Street, we dive into the 21% stock drop of $PUBM and the class action lawsuit shaking up PubMatic. Investors claim they were misled about key business risks, particularly a major DSP client shift that wasn’t disclosed until it was too late. If you’re an ad tech investor, shareholder, or just love watching Wall Street get called out, this one’s for you. Expect deep dives, sharp insights, and no sugarcoating. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t...

2025-09-1206 min

SueWallSt #022 $SNAP Ghosted Wall Street How Hidden Ad Woes Sparked a Class ActionIn this episode of Sue Wall Street we unpack the fresh class action lawsuit against $SNAP Snap Inc. Investors claim the company misled the market by hyping strong ad revenue growth while internal data showed April numbers collapsing from nine percent to just one percent. If you’re an investor, trader, or anyone tracking tech and social media stocks, this breakdown is for you. Expect sharp analysis, corporate accountability talk, and a few laughs along the way. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’...

2025-09-1206 min

SueWallSt #021 $CHTR Crash Course How Charter’s Broadband Drama Sparked a Class ActionDive into the latest episode of Sue Wall Street where we unravel the class action lawsuit against $CHTR Charter Communications. If you’re an investor, trader, or anyone tracking broadband giants, this one’s for you. We break down how the collapse of a key federal internet subsidy program triggered massive customer losses and what the company allegedly hid from shareholders. Expect sharp banter, deep dives, and no fluff. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financia...

2025-09-1206 min

SueWallSt #020 $UNCY Breakdown Did Unicycive Mislead Investors on FDA Readiness?Unicycive Therapeutics $UNCY claimed it was “very, very much ready” to launch its kidney disease drug—until back-to-back FDA setbacks tanked the stock by over 70 percent. In this episode of Sue Wall Street, Cassie and Bill unravel the lawsuit alleging executives misled investors about manufacturing readiness and FDA approval chances. Ideal for biotech watchers, retail investors, and class action followers. Expect sharp commentary, SEC breakdowns, and real accountability. Visit ZLK.com for more info. Join our WhatsApp Channel We’re not lawyers or accountants, so don’t take this as legal or financial...

2025-09-1105 min

SueWallSt #019 $AI Meltdown Did C3ai Overhype Its Growth While Hiding the Truth?C3ai $AI is in hot water after investors say the company misled them about CEO health issues and inflated revenue expectations leading to a 25 percent stock crash. In this episode of Sue Wall Street, Cassie and Bill break down the lawsuit alleging securities fraud and explain what really went down behind those bullish earnings calls. Perfect for retail investors, finance followers, and anyone tracking AI stocks. Expect deep dives, drama, and analysis with bite. Visit ZLK.com for more info. We’re not lawyers or accountants, so don’t take this as legal or f...

2025-09-1008 min

SueWallSt #018 $CAPR's Hype Meets Heartbreak Inside the Biotech Blowup at CapricorCapricor Therapeutics $CAPR claimed its miracle drug for Duchenne muscular dystrophy was cruising toward FDA approval. But behind the scenes? Alleged data concealment, canceled advisory meetings, and a crushing FDA rejection. In this episode of Sue Wall Street, Cassie and Bill unravel the class action lawsuit and the biotech optimism that may have misled investors. If you're a biotech investor, retail trader, or class action watcher this one’s for you. Expect sharp analysis, spicy quotes, and no sugarcoating. We’re not lawyers or accountants, so don’t take this as legal or financial advice. Vi...

2025-09-0307 min

SueWallSt #017 $NEOG Cracks Under Pressure Inside the $53B Food Safety Merger MeltdownWhen a $5.3 billion merger with 3M’s Food Safety division was announced, investors expected a recipe for success. But instead, $NEOG stock plunged nearly 80% amid goodwill impairments, operational chaos, and a CEO exit. In this episode of Sue Wall Street, Cassie and Bill break down the class action lawsuit against Neogen Corporation and what went wrong behind the scenes. Perfect for retail investors, financial sleuths, and anyone tracking corporate accountability. Expect deep dives, sharp banter, and SEC-level drama. We’re not lawyers or accountants, so don’t take this as legal or financial advice. Visit...

2025-09-0307 min

SueWallSt #016 $XIFR's Yieldco Mirage The 35 Percent Drop No One Saw ComingWhat happens when a clean energy giant promises reliable returns—then cuts all payouts overnight? In this episode of Sue Wall Street: Holding Wall Street Accountable, Cassie and Bill dig into the class action lawsuit against XPLR Infrastructure ($XIFR). Learn how risky financing, vague reassurances, and a surprise distribution halt led to a 35% crash and allegations of securities fraud. Perfect for dividend investors, ESG watchers, and anyone tracking the renewable energy sector. We’re not lawyers or accountants, so don’t take this as legal or financial advice. Visit ZLK.com for more info.

2025-08-2207 min

SueWallSt #015 The $IRBT Implosion Roomba Can't Sweep This One AwayLayoffs, a failed $AMZN merger, and a collapsing business model—this episode of Sue Wall Street: Holding Wall Street Accountable dives deep into the class action lawsuit against iRobot ($IRBT). Cassie and Bill unpack how post-merger optimism gave way to massive losses, skipped earnings calls, and a 51% stock crash. Perfect for retail investors, legal buffs, and anyone tracking tech-sector red flags. Expect sharp commentary, financial drama, and one robot that couldn’t clean up its mess. We’re not lawyers or accountants, so don’t take this as legal or financial advice. Visit ZLK.com for...

2025-08-2208 min

SueWallSt #014 The $WOOF Collapse When Premium Promises Go CheapPetco ($WOOF) promised a premium pet experience—but investors got a bargain-bin disaster. In this episode of Sue Wall Street: Holding Wall Street Accountable, Cassie and Bill dig into the class action lawsuit against Petco, unraveling how the company’s shift from upscale to value brands blindsided shareholders. Perfect for retail investors, legal watchers, and anyone following post-pandemic stock fallout. Expect deep dives, sharp analysis, and brutal stock chart drops. We’re not lawyers or accountants, so don’t take this as legal or financial advice. Visit ZLK.com for more info.

2025-08-2107 min

SueWallSt #013 $SAFE or Sorry How to Spot Corporate Fraud Before It Hits Your PortfolioDescription: In this episode of Sue Wall Street Holding Wall Street Accountable, Cassie and Bill break down the red flags of corporate fraud that could quietly wreck your investments. From shady earnings reports to sudden CFO resignations and sketchy auditors, learn how to safeguard your portfolio against hidden risks. Perfect for retail investors, finance enthusiasts, and anyone serious about protecting their wealth. Expect sharp insights, real-world examples, and straight talk. We’re not lawyers or accountants, so don’t take this as legal or financial advice. Visit ZLK.com for more info.

2025-08-2107 min

SueWallSt #012 $ENRN Falls The World TremblesOne company’s fraud can trigger a global meltdown. In this episode of Bulls & Betrayal: Holding Wall Street Accountable, Anna and Nate uncover how corporate scandals like $ENRN and the 2008 crash caused trillions in damage to the global economy. Perfect for investors, analysts, and finance-curious minds, this episode breaks down ripple effects—from lost jobs to regulatory overhauls. Expect sharp storytelling, real-world case studies, and hard truths. We’re not lawyers or accountants, so don’t take this as legal or financial advice. Visit ZLK.com for more info.

2025-08-2107 min

SueWallSt #011 Catching Red Flags Early $SPY EditionHundreds of securities fraud lawsuits hit the courts every year—yet most investors find out too late. In this episode of Bulls & Betrayal: Holding Wall Street Accountable, Anna and Nate break down exactly how to stay ahead of the curve. This one’s for retail investors, finance enthusiasts, and anyone holding public equities. Learn how to use SEC alerts, shareholder notices, and free portfolio monitoring tools to detect fraud early. Expect sharp insights, casual banter, and practical tips. We’re not lawyers or accountants, so don’t take this as legal or financial advice. Visit ZL...

2025-08-2108 min

SueWallSt #010 $ETHICS Sold Separately: The Real Cost of Corporate FraudWhat happens when a company chooses profits over principles? In this episode of Sue Wall Street, Cassie and Bill dive into the ethical wreckage left behind by securities fraud. It's not just about breaking the law—it’s about breaking trust with investors, employees, and the public. If you're holding $stock in any NYSE or NASDAQ company, this episode’s your reality check on why integrity should matter just as much as earnings. We’re not lawyers or accountants, so don’t take this as legal or financial advice. Visit ZLK.com for more info.

2025-08-1307 min